{"id":499751,"date":"2021-05-28T09:38:06","date_gmt":"2021-05-28T13:38:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/"},"modified":"2021-05-28T09:38:06","modified_gmt":"2021-05-28T13:38:06","slug":"hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/","title":{"rendered":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit"},"content":{"rendered":"
\n

SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) — Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) <\/strong>investors with significant losses to submit your losses now<\/a>.<\/p>\n

\n Class Period: <\/strong>June 15, 2020 – Apr. 4, 2021
Lead Plaintiff Deadline: <\/strong>June 18, 2021
Visit:<\/strong>www.hbsslaw.com\/investor-fraud\/ACAD<\/a>
Contact An Attorney Now:<\/strong>ACAD@hbsslaw.com<\/a>
844-916-0895<\/strong><\/p>\n

\n Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:<\/strong>\n <\/p>\n

The complaint alleges that Defendants misrepresented facts concerning Acadia\u2019s supplemental new drug application (\u201csNDA\u201d) for NUPLAZID\u00ae (pimavanserin), which treats dementia-related psychosis (\u201cDRP\u201d).<\/p>\n

Specifically, on July 20, 2020, Acadia announced the FDA accepted for filing the sNDA and stated that its pivotal study for the drug showed a meaningful reduction of psychosis symptoms and a nearly 3X reduction in the risk of relapse for patients continuing on pimavanserin vs. placebo. Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drug\u2019s efficacy.<\/p>\n

But the truth began to emerge on Mar. 8, 2021, when Acadia announced that on Mar. 3, 2021 the FDA informed the company that it had identified deficiencies in the sNDA.\u00a0\u00a0<\/p>\n

\n Then, on Apr. 5, 2021, Acadia announced the FDA had rejected the sNDA, citing a lack of statistical significance<\/strong> regarding some of the subgroups of dementia and inadequate numbers of patients with some less common dementia subtypes.<\/p>\n

\u201cWe\u2019re focused on investors\u2019 losses and proving Acadia misled investors by concealing FDA-related review risks for the sNDA,\u201d said Reed Kathrein, the Hagens Berman partner leading the investigation.<\/p>\n

If you are an Acadia investor and have significant losses, or have knowledge that may assist the firm\u2019s investigation, click here to discuss your legal rights with Hagens Berman<\/a>.<\/p>\n

\n Whistleblowers: <\/strong>Persons with non-public information regarding Acadia should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895<\/strong> or email ACAD@hbsslaw.com<\/a>.<\/p>\n

\n
\n About Hagens Berman<\/u>
\n <\/a>
\n
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation.\u00a0\u00a0 More about the firm and its successes is located at hbsslaw.com<\/a>. For the latest news visit our newsroom<\/u><\/a> or follow us on Twitter at @classactionlaw<\/u><\/a>.<\/p>\n

Contact: <\/u>
Reed Kathrein, 844-916-0895<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) — Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 – Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:www.hbsslaw.com\/investor-fraud\/ACADContact An Attorney Now:ACAD@hbsslaw.com844-916-0895 Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action: The complaint alleges that Defendants misrepresented facts concerning Acadia\u2019s supplemental new drug application (\u201csNDA\u201d) for NUPLAZID\u00ae (pimavanserin), which treats dementia-related psychosis (\u201cDRP\u201d). Specifically, on July 20, 2020, Acadia announced the FDA accepted for filing the sNDA and stated that its pivotal study for the drug showed a meaningful reduction of psychosis symptoms and a nearly 3X reduction in the risk of relapse for patients continuing on pimavanserin vs. placebo. Thereafter, … <\/p>\n

Continue reading “HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499751","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) — Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 – Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:www.hbsslaw.com\/investor-fraud\/ACADContact An Attorney Now:ACAD@hbsslaw.com844-916-0895 Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action: The complaint alleges that Defendants misrepresented facts concerning Acadia\u2019s supplemental new drug application (\u201csNDA\u201d) for NUPLAZID\u00ae (pimavanserin), which treats dementia-related psychosis (\u201cDRP\u201d). Specifically, on July 20, 2020, Acadia announced the FDA accepted for filing the sNDA and stated that its pivotal study for the drug showed a meaningful reduction of psychosis symptoms and a nearly 3X reduction in the risk of relapse for patients continuing on pimavanserin vs. placebo. Thereafter, … Continue reading "HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-28T13:38:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit\",\"datePublished\":\"2021-05-28T13:38:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/\"},\"wordCount\":414,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/\",\"name\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI=\",\"datePublished\":\"2021-05-28T13:38:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit - Market Newsdesk","og_description":"SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) — Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 – Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:www.hbsslaw.com\/investor-fraud\/ACADContact An Attorney Now:ACAD@hbsslaw.com844-916-0895 Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action: The complaint alleges that Defendants misrepresented facts concerning Acadia\u2019s supplemental new drug application (\u201csNDA\u201d) for NUPLAZID\u00ae (pimavanserin), which treats dementia-related psychosis (\u201cDRP\u201d). Specifically, on July 20, 2020, Acadia announced the FDA accepted for filing the sNDA and stated that its pivotal study for the drug showed a meaningful reduction of psychosis symptoms and a nearly 3X reduction in the risk of relapse for patients continuing on pimavanserin vs. placebo. Thereafter, … Continue reading \"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-28T13:38:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit","datePublished":"2021-05-28T13:38:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/"},"wordCount":414,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/","name":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI=","datePublished":"2021-05-28T13:38:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDg2MSM0MjA2Nzc3IzIwMTg1MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-encourages-acadia-pharmaceuticals-acad-investors-with-losses-to-contact-the-firm-june-18th-deadline-approaching-in-securities-fraud-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499751"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499751\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}